DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of COVID versus placebo, at three months, from a single ...

TikTok took a major step toward avoiding a U.S. ban last week. Its chief executive, Shou Zi Chew, announced that the company ...

The Defiance Quantum ETF QTUM provides broad exposure and trades at roughly 23 times cash flow. Not cheap, but not insane for a sector where winners might return 50 times. It's up almost 40% so far ...

The contract was signed, and St. Paul paid McKenzie’s nonprofit, BlackFem, $900,000, while expecting lessons on personal ...

Nigeria's government officially classifies bandits and kidnappers as terrorists, reinforcing a nationwide security emergency ...

The ruling Democratic Party on Tuesday unilaterally passed a bill to establish special tribunals for insurrection and treason ...

The traditional top-down model of strategy is obsolete – not because leaders became less capable, but because the environment became fundamentally less predictable. In an age defined by ambiguity, ...

AI chatbots are gossiping about people behind their backs, spreading rumors between systems that become increasingly ...

Deep beneath the paving stones of Jerusalem’s sacred precincts, archaeologists have uncovered a small lead disc that is ...

The Bill allows full foreign ownership in insurance companies to attract capital and expertise. It signals a major policy shift aimed at accelerating sectoral expansion while retaining regulatory ...

Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an investigational vaccine-alternative monoclonal antibody ...